# A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

> **NCT01559818** · PHASE1,PHASE2 · TERMINATED · sponsor: **Immodulon Therapeutics Ltd** · enrollment: 10 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** IMM-101

## Key facts

- **NCT ID:** NCT01559818
- **Lead sponsor:** Immodulon Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor considered no further meaningful data was being collected, nor were likely to be collected in the future.
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559818, "A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01559818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*